Related Experiment Videos
Hematologic side effects of radiolabeled immunoglobulin therapy
H M Vriesendorp1, S M Quadri, B S Andersson
1University of Texas, Anderson Cancer Center, Houston 77030, USA.
Experimental Hematology
|August 1, 1996
Summary
Radiolabeled immunoglobulin therapy (RIT) shows promise in cancer treatment but can cause bone marrow toxicity. This toxicity, primarily affecting hematopoietic stem cells, can be managed with various interventions to improve therapeutic outcomes.
Area of Science:
- Oncology
- Nuclear Medicine
- Hematology
Background:
- Radiolabeled immunoglobulin therapy (RIT) offers targeted cancer treatment.
- Bone marrow toxicity is a significant dose-limiting side effect of RIT.
- Hematopoietic stem cell damage is the primary mechanism of RIT-induced bone marrow toxicity.
Purpose of the Study:
- To review the mechanisms and management of bone marrow toxicity associated with RIT.
- To explore other hematologic side effects of RIT, including platelet consumption and lymphocyte apoptosis.
- To discuss the role of radioisotopes like 131I, 90Y, and 111In in RIT.
Main Methods:
- Review of animal toxicology studies.
- Analysis of initial clinical studies involving RIT.
- Examination of radioisotopes and chelating agents used in RIT.
Main Results:
- Bone marrow toxicity, driven by hematopoietic stem cell damage, is the main side effect of RIT.
- Platelet consumption and lymphocyte apoptosis are less significant hematologic side effects.
- The bone marrow microenvironment is generally not significantly damaged by current RIT protocols.
Conclusions:
- Bone marrow toxicity from RIT can be effectively managed through bone marrow transplantation, growth factors (like G-CSF), blood products, or RIT fractionation.
- Interventions can enhance the therapeutic ratio of RIT by mitigating bone marrow damage.
- The selection of management strategies should be tailored to the severity of bone marrow toxicity.